

e-Table 1A Diagnostic codes for multiple sclerosis and other central nervous system demyelinating diseases

Diseases	International Classification of Disease version 9 code	International Classification of Disease version 10 code
Multiple sclerosis	340	G35
Optic neuritis	377.3	H46
Acute transverse myelitis	323.82, 341.2	G37.3
Acute disseminated encephalomyelitis	323	G36.9
Demyelinating disease of central nervous system (CNS) unspecified	341.9	G37.8
Other acute disseminated demyelination	NA	G36
Neuromyelitis optica	341.0	G36.0

e-Table 1B The individual disease-modifying drugs used to treat multiple sclerosis grouped by generation and expected efficacy, along with respective Health Canada approval dates (through to 2017)

DMD generation (first or second)	Efficacy³ 3-35	Individual DMD	Brand name & related details	Health Canada approval date
First	Lower	Beta-interferon	Interferon beta-1b [Betaseron®] (0.3 mg/vial)	July 1995

			Interferon beta-1b [Extavia®] (0.3mg/vial)	November 2009
			Peginterferon beta-1a [Plegridy®] (125mcg/0.5ml); (94mcg/0.5ml); (63 mcg/0.5ml); (starter pack; 63 µg/0.5ml & 94 µg/0.5ml)	August 2015
			Interferon beta-1a [Avonex®] (30 µG/kit); (30 µG/0.5 ml)	April 1998
			Interferon beta-1a [Rebif®] (initiation pack); (8.8 µG); (11 µG); (22 µG); (44 µG); (66µG); (132µG)	February 1998
First	Lower	Glatiramer acetate	Copaxone® (20mg/1 vial); (20mg/1 ml); (40mg/1ml) Glatect® (20mg/1 ml)	October 1997, August 2017
Second	Higher	Natalizumab	Tysabri® (300mg/15ml)	September 2006
Second	Moderate	Fingolimod	Gilenya® (0.5mg capsule)	March 2011
Second	Moderate	Dimethyl fumarate	Tecfidera® (120 mg capsule) Tecfidera® (240 mg capsule)	April 2013
Second	Lower	Teriflunomide	Aubagio® (14 mg tablet)	November 2013
Second	Higher	Alemtuzumab	Lemtrada® (12 mg/1.2ml)	December 2013
Second	Higher	Ocrelizumab	Ocrevus® (300mg/ml)	August 2017